Basiliximab sarotalocan

沙巴利昔单抗

Report date: 2024/02/05 14:07:20

Base Information

Drug NameBasiliximab sarotalocan

Drug Alias NameRM-1995

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > IR700 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionAnti-IL2RACell death stimulantsPhotosensitizers

TargetsInterleukin-2 receptor alpha chain

Therapy Area/IndicationsSquamous Cell Carcinoma of Head and NeckCarcinoma, Squamous Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesRakuten Medical Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesRakuten Medical Inc

Active IndicationsN/A

Inactive IndicationsSquamous Cell Carcinoma of Head and NeckCarcinoma, Squamous Cell

Other Information

ATC CodeN/A